EURAZEO (EPA:RF) | Finanzwire

Basculer en Français

9472	Companies
185369	Keywords
117719	Articles
99261	Press releases

Home
Companies
EURAZEO

BRIEF

published on 11/06/2025 at 07:05, 28 days 22 hours ago

EURAZEO Demonstrates Robust Growth in Fundraising and Asset Rotation

Asset Management Fundraising Portfolio Growth Shareholder Returns Impact Investments
REGULATED PRESS RELEASE

published on 11/06/2025 at 07:00, 28 days 22 hours ago

EURAZEO CONTINUES TO GAIN MARKET SHARE ON FUNDRAISING AND TO IMPLEMENT ITS DYNAMIC ASSET ROTATION PLAN
Eurazeo continues to gain market share through solid fundraising and dynamic asset rotation plan, with AUM increasing to €37.4bn. Share buyback program accelerated in 2025

Share Buyback EURAZEO Fundraising AUM Asset Rotation
REGULATED PRESS RELEASE

published on 11/03/2025 at 17:35, 1 month 1 day ago

Disclosure of transactions in own shares from October 27 to October 31, 2025
BRIEF

published on 10/31/2025 at 17:50, 1 month 4 days ago

Completion of CPK Group Sale to Ferrara's European Holding

International Market CPK Group Sale Ferrara Acquisition Confectionery Merger Eurazeo Strategy
REGULATED PRESS RELEASE

published on 10/31/2025 at 17:45, 1 month 4 days ago

COMPLETION OF THE SALE OF CPK GROUP FROM EURAZEO TO THE EUROPEAN HOLDING COMPANY OF FERRARA
Eurazeo and Ferrara complete sale of CPK Group, combining confectionery leaders. CPK's iconic brands join Ferrara. Eurazeo reaffirms strategy, generating €240 million proceeds

EURAZEO Sale Confectionery CPK Group Ferrara
REGULATED PRESS RELEASE

published on 10/28/2025 at 17:35, 1 month 7 days ago

Disclosure of transactions in own shares from October 20 to October 24, 2025
BRIEF

published on 10/22/2025 at 07:30, 1 month 13 days ago

Kurma Partners Sells ImCheck Therapeutics to Ipsen for Up to €1 Billion

Cancer Immunotherapy Biotech Investments Kurma Partners ImCheck Therapeutics Ipsen Acquisition
REGULATED PRESS RELEASE

published on 10/22/2025 at 07:25, 1 month 13 days ago

KURMA PARTNERS, A MEMBER OF THE EURAZEO GROUP AND FOUNDING INVESTOR OF IMCHECK THERAPEUTICS, ANNOUNCES THE SALE OF THE BIOTECH COMPANY TO IPSEN FOR UP TO €1 BILLION
Kurma Partners, a member of the Eurazeo group, announces the sale of ImCheck Therapeutics to Ipsen for up to €1 billion. The biotech company focuses on immunotherapy for cancer treatment, confirming Kurma's success in creating and supporting biotech ventures

Immunotherapy Biotech Company Ipsen Kurma Partners ImCheck Therapeutics
REGULATED PRESS RELEASE

published on 10/20/2025 at 17:35, 1 month 15 days ago

Disclosure of transactions in own shares from October 13 to October 17, 2025
REGULATED PRESS RELEASE

published on 10/13/2025 at 17:35, 1 month 22 days ago

Disclosure of transactions in own shares from October 6 to October 10, 2025

Accesswire

Published on 12/05/2025 at 02:35, 2 hours 49 minutes ago

Future Fuels Initates Drill Permitting at Hornby; Marketing Update
Published on 12/05/2025 at 02:30, 2 hours 54 minutes ago

Klondike Gold Announces AGM Results
Published on 12/05/2025 at 01:00, 4 hours 24 minutes ago

BEACN Closes First Tranche of Non-Brokered Private Placement
Published on 12/04/2025 at 23:05, 6 hours 19 minutes ago

BlackBerry to Announce Third Quarter Fiscal Year 2026 Results on December 18, 2025
Published on 12/04/2025 at 23:00, 6 hours 24 minutes ago

NXT Energy Solutions Completes Data Acquisition for SFD Survey

View all ACCESSWIRE

EQS Group

Published on 12/05/2025 at 03:30, 1 hour 54 minutes ago

CGTN: What makes cooperation between China and France a two-way success
Published on 12/04/2025 at 23:50, 5 hours 34 minutes ago

EQS-Adhoc: Dexus Finance Pty Limited: Dexus prices A$500 million of subordinated notes
Published on 12/04/2025 at 20:25, 8 hours 59 minutes ago

Newmark Appoints Globally Recognized Real Estate Executive Peter Trollope to Lead Occupier Solutions
Published on 12/04/2025 at 20:15, 9 hours 9 minutes ago

Galimedix Therapeutics presents compelling Phase 1 study results showing excellent safety and pharmacokinetics with oral small molecule GAL-101 at CTAD 2025
Published on 12/04/2025 at 19:10, 10 hours 14 minutes ago

SCHOTT Pharma’s preliminary results for fiscal year 2025; outlook for FY 2026 and update of mid-term guidance

Les Echos

Published on 12/04/2025 at 18:00, 11 hours 24 minutes ago

Information concerning the total number of voting rights and shares in the share capital as of November 28, 2025
Published on 12/04/2025 at 17:45, 11 hours 39 minutes ago

MONTHLY INFORMATION RELATING TO THE TOTAL NUMBER OF VOTING RIGHTS AND SHARES MAKING UP THE SHARE CAPITAL
Published on 12/04/2025 at 17:44, 11 hours 40 minutes ago

Net profit attributable to owners of the parent up by 63% to €122 million, driven by business resilience and the improvement in Elior's contribution
Published on 12/04/2025 at 07:01, 22 hours 23 minutes ago

bioMérieux launches leading endocrinology testing offer dedicated to enhancing equine health
Published on 12/03/2025 at 18:00, 1 day 11 hours ago

Declaration of voting rights at the end of November 2025

View all LES ECHOS COMFI WIRE